Sol-Gel Technologies (SLGL) Retained Earnings (2016 - 2025)
Sol-Gel Technologies (SLGL) reported Retained Earnings of -$237.0 million for Q4 2025, down 2.65% year-over-year from -$243.5 million in Q4 2024, and down 1.28% on a QoQ basis from -$234.0 million in Q3 2025.
Sol-Gel Technologies (SLGL) has 10 years of Retained Earnings data on file, last reported at -$237.0 million in Q4 2025.
- Quarterly Retained Earnings fell 2.65% year-over-year to -$237.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$237.0 million (down 2.65% YoY) and the FY2025 annual result came in at -$237.0 million, down 2.65% from the prior year.
- Retained Earnings fell to -$237.0 million in Q4 2025 per SLGL's latest filing, from -$234.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$178.1 million in Q4 2021 and bottomed at -$239.7 million in Q1 2025.
- The 5-year median for Retained Earnings is -$212.6 million (2023), against an average of -$209.6 million.
- The widest annual swing landed in 2021, when Retained Earnings decreased 16.49%; it then rose 4.96% in 2022.
- Tracing SLGL's Retained Earnings over 5 years: stood at -$178.1 million in 2021, then slipped by 8.38% to -$193.1 million in 2022, then retreated by 14.11% to -$220.3 million in 2023, then decreased by 4.8% to -$230.9 million in 2024, then declined by 2.65% to -$237.0 million in 2025.
- Per Business Quant, the three latest SLGL Retained Earnings figures stand at -$237.0 million (Q4 2025), -$234.0 million (Q3 2025), and -$228.1 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Sol-Gel Technologies | 205.76 Mn | 194.73 Mn | - | -237.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -237.01 Mn |
| Sep 30, 2025 | -234.02 Mn |
| Jun 30, 2025 | -228.08 Mn |
| Mar 31, 2025 | -239.69 Mn |
| Dec 31, 2024 | -230.88 Mn |
| Sep 30, 2024 | -225.04 Mn |
| Jun 30, 2024 | -224.67 Mn |
| Mar 31, 2024 | -226.65 Mn |
| Dec 31, 2023 | -220.30 Mn |
| Sep 30, 2023 | -215.47 Mn |
| Jun 30, 2023 | -209.76 Mn |
| Mar 31, 2023 | -203.33 Mn |
| Dec 31, 2022 | -193.07 Mn |
| Sep 30, 2022 | -187.28 Mn |
| Jun 30, 2022 | -183.87 Mn |
| Mar 31, 2022 | -183.74 Mn |
| Dec 31, 2021 | -178.14 Mn |
| Sep 30, 2021 | -192.17 Mn |
| Jun 30, 2021 | -193.46 Mn |
| Mar 31, 2021 | -185.43 Mn |
| Dec 31, 2020 | -181.36 Mn |
| Sep 30, 2020 | -174.88 Mn |
| Jun 30, 2020 | -166.25 Mn |
| Mar 31, 2020 | -159.18 Mn |
| Dec 31, 2019 | -152.07 Mn |
| Sep 30, 2019 | -145.47 Mn |
| Jun 30, 2019 | -138.12 Mn |
| Mar 31, 2019 | -133.19 Mn |
| Dec 31, 2018 | -127.46 Mn |
| Mar 31, 2018 | -100.97 Mn |
| Dec 31, 2017 | -95.26 Mn |
| Dec 31, 2016 | -63.69 Mn |